{"schema_version":"secwatch.filing_event.v1","accession":"0001619856-25-000070","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.942301+00:00","generated_at":"2026-05-16T21:13:14.039066+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Caribou Biosciences reports Q3 2025 clinical data: vispa-cel 86% ORR, CB-011 92% ORR; cash $159.2M","bullets":["Vispa-cel ANTLER phase 1: 86% ORR, 63% CR, 53% PFS at 12mo in 35 patients with optimized profile (≥2 HLA match, young donor).","CB-011 CaMMouflage phase 1: 92% ORR, 75% ≥CR, 91% MRD-negativity in 12 BCMA-naïve patients at recommended dose.","Cash, equivalents, and marketable securities $159.2M as of Sep 30, 2025; expected to fund operations into 2H 2027.","Q3 2025 revenue $2.2M (vs $2.0M Q3 2024); R&D expenses $22.4M (down from $30.4M); G&A $9.2M (down from $9.8M).","FDA recommends randomized controlled trial for vispa-cel pivotal phase 3 in 2L LBCL; company to refine design with FDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001619856-25-000070","json":"https://secwatch.observer/filing/0001619856-25-000070.json","markdown":"https://secwatch.observer/filing/0001619856-25-000070.md","text":"https://secwatch.observer/filing/0001619856-25-000070.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000161985625000070/0001619856-25-000070-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000161985625000070/crbu-20251112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:13:14.039066+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}